Home > Haematology > EHA 2019 > Lymphoid Malignancies > Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Conference
EHA 2019
Trial
Phase 3, ECHELON-1

Additional analysis and 3-year update of results from ECHELON-1, a frontline phase 3 trial evaluating brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in stage III or IV frontline classical Hodgkin lymphoma (HL) patients, resulted in a statistically significant improvement in modified progression-free survival (PFS) for the brentuximab vedotin + AVD arm vs the control arm of ABVD, as assessed by independent review [1].

Brentuximab vedotin is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and expressed on the surface of several types of peripheral T-cell lymphomas. The intention-to-treat analysis examined PFS outcomes per investigator assessment in the population of 1,334 patients <60 years old at 3 years, by cycle 2 positron-emission tomography (PET2...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on